Contrasting effects of activating mutations of GαS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells

M. Ludgate, V. Gire, M. Crisp, R. Ajjan, A. Weetman, M. Ivan, D. Wynford-Thomas

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The cyclic AMP pathway is a major regulator of thyrocyte function and proliferation and, predictably, its inappropriate activation is associated with a sub-set of human thyroid tumours. Activating mutations are, however, more common in the thyrotropin receptor (TSHR) than in its downstream transducer, Gαs. To investigate whether this reflects an inherent difference in their oncogenic potency, we compared the effects of retrovirally-transduced mutant (A623I) TSHR or (Q227L) Gαs (GSP), using the rat thyroid cell line FRTL5 and primary human thyrocytes. In FRTL5, expression of GSP or mutant (m) TSHR induced a 2-3-fold increase in basal levels of cAMP. This was associated with TSH-independent proliferation (assessed by both cell number and DNA synthesis) and function (as shown by increased expression of thyroglobulin (Tg) and the sodium/iodide symporter). In primary cultures, expression of mTSHR, but not GSP, consistently induced formation of colonies with epithelial morphology and thyroglobulin expression, capable of 10-15 population doublings (PD) compared to less than three in controls. Thus, while mTSHR and GSP exert similar effects in FRTL5, use of primary cultures reveals a major difference in their ability to induce sustained proliferation in normal human thyrocytes, and provides the first direct evidence that mTSHR is sufficient to initiate thyroid tumorigenesis.

Original languageEnglish (US)
Pages (from-to)4798-4807
Number of pages10
JournalOncogene
Volume18
Issue number34
DOIs
StatePublished - Aug 26 1999

Fingerprint

Thyrotropin Receptors
Thyroid Gland
Thyroglobulin
Mutation
Transducers
Cyclic AMP
Carcinogenesis
Cell Count
Cell Line
DNA
Population
Thyroid Epithelial Cells
Neoplasms

Keywords

  • Cyclic AMP
  • G protein
  • Oncogene
  • TSH receptor
  • Thyroid

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Contrasting effects of activating mutations of GαS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells. / Ludgate, M.; Gire, V.; Crisp, M.; Ajjan, R.; Weetman, A.; Ivan, M.; Wynford-Thomas, D.

In: Oncogene, Vol. 18, No. 34, 26.08.1999, p. 4798-4807.

Research output: Contribution to journalArticle

Ludgate, M. ; Gire, V. ; Crisp, M. ; Ajjan, R. ; Weetman, A. ; Ivan, M. ; Wynford-Thomas, D. / Contrasting effects of activating mutations of GαS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells. In: Oncogene. 1999 ; Vol. 18, No. 34. pp. 4798-4807.
@article{5298e09c8def468ba9e5374c7a474607,
title = "Contrasting effects of activating mutations of GαS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells",
abstract = "The cyclic AMP pathway is a major regulator of thyrocyte function and proliferation and, predictably, its inappropriate activation is associated with a sub-set of human thyroid tumours. Activating mutations are, however, more common in the thyrotropin receptor (TSHR) than in its downstream transducer, Gαs. To investigate whether this reflects an inherent difference in their oncogenic potency, we compared the effects of retrovirally-transduced mutant (A623I) TSHR or (Q227L) Gαs (GSP), using the rat thyroid cell line FRTL5 and primary human thyrocytes. In FRTL5, expression of GSP or mutant (m) TSHR induced a 2-3-fold increase in basal levels of cAMP. This was associated with TSH-independent proliferation (assessed by both cell number and DNA synthesis) and function (as shown by increased expression of thyroglobulin (Tg) and the sodium/iodide symporter). In primary cultures, expression of mTSHR, but not GSP, consistently induced formation of colonies with epithelial morphology and thyroglobulin expression, capable of 10-15 population doublings (PD) compared to less than three in controls. Thus, while mTSHR and GSP exert similar effects in FRTL5, use of primary cultures reveals a major difference in their ability to induce sustained proliferation in normal human thyrocytes, and provides the first direct evidence that mTSHR is sufficient to initiate thyroid tumorigenesis.",
keywords = "Cyclic AMP, G protein, Oncogene, TSH receptor, Thyroid",
author = "M. Ludgate and V. Gire and M. Crisp and R. Ajjan and A. Weetman and M. Ivan and D. Wynford-Thomas",
year = "1999",
month = "8",
day = "26",
doi = "10.1038/sj.onc.1202864",
language = "English (US)",
volume = "18",
pages = "4798--4807",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "34",

}

TY - JOUR

T1 - Contrasting effects of activating mutations of GαS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells

AU - Ludgate, M.

AU - Gire, V.

AU - Crisp, M.

AU - Ajjan, R.

AU - Weetman, A.

AU - Ivan, M.

AU - Wynford-Thomas, D.

PY - 1999/8/26

Y1 - 1999/8/26

N2 - The cyclic AMP pathway is a major regulator of thyrocyte function and proliferation and, predictably, its inappropriate activation is associated with a sub-set of human thyroid tumours. Activating mutations are, however, more common in the thyrotropin receptor (TSHR) than in its downstream transducer, Gαs. To investigate whether this reflects an inherent difference in their oncogenic potency, we compared the effects of retrovirally-transduced mutant (A623I) TSHR or (Q227L) Gαs (GSP), using the rat thyroid cell line FRTL5 and primary human thyrocytes. In FRTL5, expression of GSP or mutant (m) TSHR induced a 2-3-fold increase in basal levels of cAMP. This was associated with TSH-independent proliferation (assessed by both cell number and DNA synthesis) and function (as shown by increased expression of thyroglobulin (Tg) and the sodium/iodide symporter). In primary cultures, expression of mTSHR, but not GSP, consistently induced formation of colonies with epithelial morphology and thyroglobulin expression, capable of 10-15 population doublings (PD) compared to less than three in controls. Thus, while mTSHR and GSP exert similar effects in FRTL5, use of primary cultures reveals a major difference in their ability to induce sustained proliferation in normal human thyrocytes, and provides the first direct evidence that mTSHR is sufficient to initiate thyroid tumorigenesis.

AB - The cyclic AMP pathway is a major regulator of thyrocyte function and proliferation and, predictably, its inappropriate activation is associated with a sub-set of human thyroid tumours. Activating mutations are, however, more common in the thyrotropin receptor (TSHR) than in its downstream transducer, Gαs. To investigate whether this reflects an inherent difference in their oncogenic potency, we compared the effects of retrovirally-transduced mutant (A623I) TSHR or (Q227L) Gαs (GSP), using the rat thyroid cell line FRTL5 and primary human thyrocytes. In FRTL5, expression of GSP or mutant (m) TSHR induced a 2-3-fold increase in basal levels of cAMP. This was associated with TSH-independent proliferation (assessed by both cell number and DNA synthesis) and function (as shown by increased expression of thyroglobulin (Tg) and the sodium/iodide symporter). In primary cultures, expression of mTSHR, but not GSP, consistently induced formation of colonies with epithelial morphology and thyroglobulin expression, capable of 10-15 population doublings (PD) compared to less than three in controls. Thus, while mTSHR and GSP exert similar effects in FRTL5, use of primary cultures reveals a major difference in their ability to induce sustained proliferation in normal human thyrocytes, and provides the first direct evidence that mTSHR is sufficient to initiate thyroid tumorigenesis.

KW - Cyclic AMP

KW - G protein

KW - Oncogene

KW - TSH receptor

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=0033607019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033607019&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1202864

DO - 10.1038/sj.onc.1202864

M3 - Article

C2 - 10490813

AN - SCOPUS:0033607019

VL - 18

SP - 4798

EP - 4807

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 34

ER -